SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO(2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

WO 02/76925 (Eli Lilly) describes a series of compounds which are claimed to be histamine H3 antagonists. WO 02/055496 (GlaxoSmithKline) describes a series of piperidine and piperazine derivatives which are claimed to be inducers of LDL-receptor expression. WO 02/12214 (Ortho McNeil Pharmaceutical Inc) describes a series of substituted aryloxyalkylamines which are claimed to be histamine H3 antagonists.

The histamine H3 receptor is expressed in both the mammalian central nervous system (CNS), and in peripheral tissues (Leurs et al., (1998), Trends Pharmacol. Sci. 19, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic, adrenergic and cholinergic neurons (Schlicker et al., (1994), Fundam. Clin. Pharmacol. 8, 128-137). Additionally, in vitro and in vivo studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera et al., (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni et al., (1999), Behav. Brain Res. 104, 147-155). These data suggest that novel H3 antagonists and/or inverse agonists such as the current series could be useful for the treatment of cognitive impairments in neurological diseases such as Alzheimer's disease and related neurodegenerative disorders.

The present invention provides, in a first aspect, a compound of formula (I):

$$(R^4)_r$$
 $(R^2)_n$ 
 $(CH_2)_m$ 
 $(R^3)_r$ 

wherein:

 $R^1$  represents hydrogen,  $-C_{1-8}$  alkyl,  $-C_{1-8}$  alkoxy,  $-C_{3-8}$  cycloalkyl,  $-C_{1-8}$  alkyl- $-C_{3-8}$  cycloalkyl, aryl, heterocyclyl, heterocyclyl,  $-C_{1-8}$  alkyl-aryl,  $-C_{1-8}$  alkyl-heteroaryl,  $-C_{1-8}$  alkyl-heteroaryl

heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl, -heteroaryl, -heteroaryl, -heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heterocyclyl, -heterocyclyl-heterocyclyl, -heterocyclyl,

wherein R<sup>1</sup> may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, COOR<sup>15</sup>, cyano, -C<sub>1-6</sub> alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C<sub>1-6</sub> alkyl (optionally substituted by a COOR<sup>15</sup> group), C<sub>2-6</sub> alkynyl (optionally substituted by a COOR<sup>15</sup> group), C<sub>1-6</sub> alkoxy (optionally substituted by a COOR<sup>15</sup> group),

- 10 pentafluoroethyl,  $C_{1-8}$  alkoxy,  $C_{2-8}$  alkenoxy, aryl, aryl $C_{1-8}$  alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, - $C_{1-8}$  alkyl-CO-aryl, aryl $C_{1-8}$  alkoxy,  $C_{1-8}$  alkylthio,  $C_{1-8}$  alkoxy $C_{1-8}$  alkyl,  $C_{3-7}$  cycloalkyl,  $C_{3-7}$  cycloalkyl $C_{1-8}$  alkoxy,  $C_{1-8}$  alkoxycarbonyl,  $C_{1-8}$  alkylsulfonyl,  $C_{1-8}$  alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl $C_{1-8}$  alkyl,
- aryloxy, C<sub>1-8</sub> alkylsulfonamido, C<sub>1-8</sub> alkylamido, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-8</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-8</sub> alkyl, arylsulfonamido, arylsulfonamidoC<sub>1-8</sub> alkyl, or a group -COR<sup>15</sup>, -NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup> or -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, wherein R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen, C<sub>1-8</sub> alkyl or C<sub>3-8</sub> cycloalkyl or together may be fused to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an

O or S atom and optionally substituted by a halogen, C<sub>1-6</sub> alkyl or -C<sub>1-6</sub> alkylC<sub>1-6</sub> alkoxy group;

Z-represents a bond, CO, N(R<sup>10</sup>)CO or SO<sub>2</sub>, such that when R<sup>1</sup> represents hydrogen, Z-represents NR<sup>10</sup>CO;

25 p is 1 or 2;

30

m, n and r independently represent 0, 1 or 2;

 $R^2$  represents halogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two  $R^2$  groups may instead be linked to form a phenyl ring;  $R^4$  represents  $C_{1-6}$  alkyl, or when r represents 2, two  $R^4$  groups may instead together form a bridged  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group;

 $R^{10}$  represents hydrogen or  $C_{1-\theta}$  alkyl, or  $R^{10}$ , together with the nitrogen to which it is attached and  $R^1$  forms a nitrogen containing heterocyclic group;  $R^3$  represents - $(CH_2)_q$ -NR<sup>11</sup>R<sup>12</sup> or a group of formula (i):

$$-(CH_2)_f$$
  $(R^{14})_k$   $(I)_h$   $(I)_h$ 

35 wherein q is 2, 3 or 4;

R<sup>11</sup> and R<sup>12</sup> independently represent C<sub>1-6</sub> alkyl or C<sub>3-8</sub> cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R<sup>17</sup> groups;

 $R^{13}$  represents hydrogen,  $C_{1-8}$  alkyl,  $-C_{1-8}$  alkyl- $C_{1-8}$  alkoxy,  $C_{3-8}$  cycloalkyl,  $-C_{1-8}$  alkyl-aryl or heterocyclyl;

- $R^{14}$  and  $R^{17}$  independently represent halogen,  $C_{1-8}$  alkyl, haloalkyl, OH, di $C_{1-8}$  alkylamino,  $C_{1-8}$  alkoxy or heterocyclyl;
- f and k independently represent 0, 1 or 2; g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; with the proviso that when m represents 1, n and r both represent 0 and R³ represents – (CH<sub>2</sub>)<sub>3</sub>-N-piperidine or –(CH<sub>2</sub>)<sub>3</sub>-N(ethyl)<sub>2</sub>, R¹-Z represents a group other than methyl, -CO-O-C(CH<sub>3</sub>)<sub>3</sub> or benzyl;
- and with the proviso that when m, n and r all represent 0, p represents 1, R³ represents (CH<sub>2</sub>)<sub>3</sub>-N-pyrrolidine or –(CH<sub>2</sub>)<sub>3</sub>-N-piperidine, R¹ represents benzyl, Z represents a group other than a bond;
  - and with the proviso that when m, n and r all represent 0, p represents 1,  $R^3$  represents— $(CH_2)_3$ -N-piperidine,  $R^1$  represents isopropyl, Z represents a group other than a bond;
- and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R<sup>3</sup> represents—(CH<sub>2</sub>)<sub>3</sub>-N-piperidine, R<sup>1</sup> represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond; and with the proviso that when m and n both represent 0, R<sup>3</sup> represents –(CH<sub>2</sub>)<sub>3</sub>-N(ethyl)<sub>2</sub>, p represents 1, r represents 2 and R<sup>1</sup> and R<sup>4</sup> both represent methyl, Z
- 20 represents a group other than a bond; or a pharmaceutically acceptable salt thereof.

In one particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein:

- R<sup>1</sup> represents a group other than hydrogen, -C<sub>1-6</sub> alkoxy or -C<sub>1-6</sub> alkyl-C<sub>3-6</sub> cycloalkyl; and R<sup>1</sup> is optionally substituted by one or more substituents other than COOR<sup>15</sup>, -C<sub>1-6</sub> alkyl-cyano, C<sub>1-6</sub> alkyl substituted by a COOR<sup>15</sup> group), C<sub>2-6</sub> alkenyl (optionally substituted by a COOR<sup>15</sup> group), C<sub>1-6</sub> alkynyl (optionally substituted by a COOR<sup>15</sup> group), C<sub>1-6</sub> alkoxy (optionally substituted by a COOR<sup>15</sup> group), C<sub>2-6</sub> alkenoxy, aryl, arylC<sub>1-6</sub> alkyl, -CO-aryl
- 30 (optionally substituted by a halogen atom), -CO-heteroaryl, -C<sub>1-6</sub> alkyl-CO-aryl or C<sub>3-7</sub> cycloalkyl; and
  - $R^{15}$  and  $R^{16}$  independently represent a group other than  $C_{3-8}$  cycloalkyl or together may be fused to form an unsubstituted 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom; and
- r represents 0; and two R<sup>2</sup> groups are not linked to form a phenyl ring; and R<sup>11</sup> and R<sup>12</sup> independently represent a group other than C<sub>3-8</sub> cycloalkyl; and R<sup>13</sup> represents a group other than -C<sub>1-8</sub> alkyl-C<sub>3-8</sub> cycloalkyl.
- In a second particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein m represents 0 or 2.

In a further particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein Z represents CO, CONR<sup>10</sup> or SO<sub>2</sub>.

Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C<sub>1-4</sub> alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.

The term "aryl" includes single and fused rings wherein at least one ring is aromatic, for example, phenyl, naphthyl, tetrahydronaphthalenyl, indanyl or fluorenyl.

The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated ring or a 4-7 membered saturated or partially unsaturated ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, diazepanyl, azepanyl and azocanyl. Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl and dihydroisoquinolinyl.

20

15

The term "nitrogen containing heterocyclyl" is intended to represent any heterocyclyl group as defined above which contains a nitrogen atom.

- The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such fused aromatic rings include furopyridinyl and benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothianyl, benzothiazolyl, benzothiazolyl, benzothiazolyl, benzothiadiazolyl, benzothiadiazolyl, and the like.
  - 35 Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy, psychlatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity, asthma,

alkenyl (eg. ethenyl) optionally substituted by COOR<sup>15</sup> (eg. COOMe); C<sub>3-7</sub> cycloalkyl (eg. cyclopentyl); C<sub>1-6</sub> alkylsulfonyl (eg. –SO<sub>2</sub>Me); C<sub>1-6</sub> alkenoxy (eg. –OCH<sub>2</sub>CH=CH<sub>2</sub>); C<sub>1-6</sub> alkylthio (eg. –S-ethyl); NR<sup>15</sup>R<sup>16</sup> (eg. N(Me)<sub>2</sub>); -C<sub>1-6</sub> alkyl-aryl (eg. benzyl); aryl (eg. phenyl); -CO-aryl (eg. –CO-phenyl) optionally substituted by halogen (eg. chlorine); -CO-heteroaryl (eg. –CO-azetidinyl); -CO-heterocyclyl (eg. –CO-tetrahydropyranyl); -COOR<sup>15</sup> (eg. COOH, COOMe or COOt-butyl); -COR<sup>15</sup> (eg. –CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclopentyl or -CO-cyclohexyl); -CONR<sup>15</sup>R<sup>16</sup> (eg. –CONH<sub>2</sub>, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-piperazinyl, -CO-piperidinyl, -CO-thiomorpholinyl) optionally substituted by C<sub>1-6</sub> alkyl (eg. methyl), halogen (eg. fluorine) or -C<sub>1-6</sub> alkylC<sub>1-6</sub> alkoxy (eg. –CH<sub>2</sub>-OMe); or -C<sub>1-6</sub> alkyl-CO-aryl (eg. –CH<sub>2</sub>COphenyl) groups.

More preferably, R<sup>1</sup> is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. fluorine); oxo; cyano; -CONR<sup>15</sup>R<sup>16</sup> (eg. -CO-pyrrolidinyl) or -COR<sup>15</sup> (eg. -CO-isopropyl, -CO-cyclopropyl or -CO-cyclobutyl).

Preferably, Z represents a bond, CO or CONR<sup>10</sup>. More preferably, Z represents bond or CO, especially CO.

Preferably, R<sup>10</sup> represents hydrogen or C<sub>1-6</sub> alkyl.

20 Preferably, m is 0 or 2, more preferably 0.

Preferably, n is 0 or 1, more preferably n is 0.

When n represents 1,  $R^2$  is preferably halogen (eg. chlorine, bromine or fluorine), trifluoromethyl, cyano or  $C_{1-6}$  alkyl (eg. methyl). Preferably, r is 0.

When r represents 1 or 2,  $R^2$  is preferably  $C_{1-8}$  alkyl (eg. methyl) or two  $R^4$  groups together form a bridged  $CH_2$  group.

Preferably, p is 1.

15

Preferably, R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>11</sup>R<sup>12</sup>.

When R³ represents a group of formula (i), preferably f is 0 or 1, g is 2, h is 1, k is 0 and R¹³ represents hydrogen, optionally substituted C₁₆ alkyl (eg. ethyl, methylpropyl, isopropyl or methoxyethyl), C₃₊₆ cycloalkyl (eg. cyclopropyl, cyclobutyl or cyclopentyl) or C₁₊₆ alkyl-C₃₊₆ cycloalkyl (eg. –CH₂-cyclopropyl).

When R³ represents a group of formula (i), more preferably f is 0, g is 2, h is 1, k is 0 and R¹³ represents C₁₊₆ alkyl (eg. isopropyl) or C₃₊₆ cycloalkyl (eg. cyclopropyl or cyclobutyl).

- Preferably, q is 2 or 3, more preferably 3.

  Preferably, R<sup>11</sup> and R<sup>12</sup> independently represent C<sub>1-6</sub> alkyl (eg. methyl) or C<sub>3-8</sub> cycloalkyl (eg. cyclopentyl) or NR<sup>11</sup>R<sup>12</sup> represents a heterocyclic group (eg. piperidinyl, pyrrolidinyl, thiomorpholinyl, azepanyl or azocanyl optionally substituted by one or more halogen (eg. fluorine) or C<sub>1-6</sub> alkyl (eg. methyl or ethyl).
- 40 More preferably NR<sup>11</sup>R<sup>12</sup> represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C<sub>1-6</sub> alkyl (eg. methyl or ethyl), especially unsubstituted piperidine.

Preferably, -O-R<sup>3</sup> is present at the para position of the phenyl group with respect to the rest of the compound.

Preferred compounds according to the invention include examples E1-E503 as shown below, or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphuric, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention. For example, when R³ represents (CH₂)qNR¹¹R¹² and NR¹¹R¹² represents a nitrogen containing heterocyclyl group substituted by one or more C₁-θ alkyl groups it will be appreciated that the present invention extends to cover diastereomeric and enantiomeric compounds.

20

5

10

15

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)

25

$$(R^4)_r$$
 $(R^2)_n$ 
 $(CH_2)_m$ 
 $(II)$ 

wherein R<sup>1</sup>, Z, R<sup>4</sup>, p, m, r, R<sup>2</sup> and n are as defined above, with a compound of formula R<sup>3</sup>-L<sup>1</sup>, wherein R<sup>3</sup> is as defined above for R<sup>3</sup> or a group convertible thereto and L<sup>1</sup> represents a suitable leaving group such as a halogen atom (eg. bromine or chlorine) or an optionally activated hydroxyl group; or

(b) preparing a compound of formula (I) wherein Z represents CO by reacting a compound of formula (III)

35

30

$$(R^4)_r$$
 $(R^2)_n$ 
 $(CH_2)_m$ 
 $O-R^3$ 

or a protected derivative thereof, wherein R<sup>4</sup>, r, p, m, R<sup>2</sup>, n and R<sup>3</sup> are as defined above, with a compound of formula R<sup>1</sup>-COX, wherein R<sup>1</sup> is as defined above and X represents a suitable leaving group such as an activated hydroxy group, a suitable halogen atom or benzotriazolyl; or

- (c) preparing a compound of formula (I) wherein Z represents SO<sub>2</sub> by reacting a compound of formula (III) as defined above with a compound of formula R<sup>1</sup>-SO<sub>2</sub>Cl, wherein R<sup>1</sup> is as defined above; or
- (d) preparing a compound of formula (I) wherein Z represents NR¹ºCO by reacting a compound of formula (III) as defined above with a compound of formula R¹-N=C=O, wherein R¹ is as defined above; or
- (e) preparing a compound of formula (I) wherein Z represents CONR<sup>10</sup> by reacting a compound of formula (III) as defined above, sequentially with phosgene in a solvent such as toluene followed by a compound of formula R<sup>10</sup>R<sup>1</sup>-NH, in a solvent such as dichloromethane, wherein R<sup>1</sup> and R<sup>10</sup> are as defined above; or
- (f) preparing a compound of formula (I) wherein m represents 1 by reacting a compound of formula (IV)

$$0 \longrightarrow 0 \longrightarrow R^3$$

with a compound of formula (XI)

10

15

20

$$R_1 = Z \qquad \qquad (R^4)_r \qquad N \qquad H$$

$$(XI)$$

or an optionally protected derivative thereof, wherein R<sup>4</sup>, r, R<sup>2</sup>, n, R<sup>3</sup>, R<sup>1</sup>, Z and p are as defined above under reducing conditions; or

- (g) deprotecting a compound of formula (I) which is protected; and
- (h) interconversion to other compounds of formula (l).

5

When  $R^3$  represents  $-(CH_2)_q$ - $NR^{11}R^{12}$ , process (a) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of an activating reagent such as potassium iodide at an appropriate temperature such as reflux.

10

When a group  $R^{3'}$  convertible to  $R^3$  represents, for example,  $L^2$ -( $CH_2$ )<sub>q</sub>-, process (a) typically comprises an alkylation reaction using analogous conditions to those described above.

When R³ represents a group of formula (i) and L¹ represents an optionally activated hydroxyl group, process (a) typically comprises the use of a phosphine such as triphenylphosphine in a suitable solvent such as tetrahydrofuran, followed by addition of an azodicarboxylate such as diethylazodicarboxylate at a suitable temperature such as room temperature.

20

Process (b) typically comprises the use of an appropriate solvent such as dichloromethane optionally in the presence of an organic or inorganic base such as potassium carbonate or in the presence of a suitable coupling agent such as 1,3-dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.

25

Processes (c) and (d) typically comprise the use of a suitable solvent such as 2-butanone.

Process (e) typically comprises the use of a suitable base, such as triethylamine.

30

Process (f) comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, followed by optional deprotection in the event that the compound of formula (XI) is a protected derivative.

35

40

In process (g), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-

trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-COCF<sub>3</sub>) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.

Process (h) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, compounds of formula (I) wherein R³ represents a group of formula (i) may be interconverted at the R¹³ position by reaction with an alkyl halide such as 1-chloro-2-methoxyethane in the presence of a base such as potassium carbonate in a suitable solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide. Such interconversion may also be carried out by reductive amination, for example, with acetone in the presence of a borohydride such as sodium triacetoxyborohydride and optionally an acid such as acetic acid in a suitable solvent such as dichloromethane.

Compounds of formula (II) and (III) wherein m is 1 or 2 may be prepared in accordance with the following scheme:

$$(|V|) \qquad (|R^2|_n) \qquad H \qquad (|R^2|_n) \qquad (|R^$$

20

10

15

wherein  $R^4$ , r,  $R^2$ , n,  $R^3$ , p are as defined above and the compound of formula (V) may be optionally protected.

25 Step (i) may be performed in an analogous manner to that described for process (f) above.

Compounds of formula (III) wherein m is 0 may be prepared in accordance with the following scheme:

H

$$(R^4)$$
 $(R^2)_n$ 
 $(R^2)_n$ 

wherein  $R^4$ , r, p,  $R^2$ , n and  $R^3$  are as defined above and  $P^1$  represents a suitable protecting group (such as Boc).

- Step (i) may be performed when P<sup>1</sup> represents Boc by reacting a compound of formula (IX) with di-t-butyl carbonate in the presence of a suitable base (eg. triethylamine) in the presence of a suitable solvent (eg. dichloromethane) at a suitable temperature (eg. room temperature).
- Step (ii) may be performed in an analogous manner to the procedures shown below for the preparation of compounds of formula (IV).

15

Step (iii) typically comprises a deprotection reaction, for example, when P<sup>1</sup> represents Boc, deprotection may typically comprise reaction of a compound of formula (III)<sup>pi</sup> with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.

Compounds of formula (III) wherein m is 2 may be prepared in accordance with the following scheme:

$$(R^4)_r \qquad (XII)$$

$$(R^2)_n \qquad (R^2)_n \qquad (R^2)_n$$

$$(XIII)$$

$$(R^4)_r \qquad (R^2)_n \qquad (R^2)_n$$

$$(III)^{pii}$$

$$(R^4)_r \qquad (R^2)_n \qquad (R^2)_n$$

$$(R^4)_r \qquad (R^2)_n \qquad (R^2)_n$$

$$(III)^{pii}$$

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n, p, r are as defined above, P<sup>2</sup> represents a suitable protecting group such as Boc and L<sup>5</sup> represents a suitable leaving group such as a halogen atom (eg. bromine).

Step (i) typically comprises reaction of a compound of formula (XII) with a compound of formula (XIII) in the presence of an inert solvent such as dimethylformamide or acetonitrile.

Step (ii) typically comprises a deprotection reaction, for example, when P<sup>2</sup> represents Boc, deprotection may typically comprise reaction of a compound of formula (III)<sup>pii</sup> with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.

5

Compounds of formula (IV) wherein R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>11</sup>R<sup>12</sup> may be prepared in accordance with the following scheme:

5

20

$$(R^{2})_{n}$$

$$(IV)^{a}$$

wherein R<sup>2</sup>, n, q, R<sup>11</sup>, R<sup>12</sup> are as defined above and L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup> and L<sup>4</sup> represent suitable leaving groups (eg. halogen atoms, such as bromine or chlorine).

Steps (i), (ii) and (iii) may be performed using similar conditions to those described for process (a) above.

Compounds of formula (IV) wherein R<sup>3</sup> represents a group of formula (i) as defined above may be prepared in accordance with the following scheme:

$$(R^{2})_{n}$$

$$O - H$$

$$Step (i)$$

$$(VI)$$

$$(R^{14})_{k}$$

$$H$$

$$O - (CH_{2})_{i}$$

$$(VI)^{n}$$

$$(VII)$$

$$(VIII)$$

wherein R<sup>2</sup>, n, f, g, h, k, are as defined above, L<sup>4</sup> represents a suitable leaving group such as a halogen atom or a hydroxyl group and R<sup>13a</sup> is as defined above for R<sup>13</sup> or a protecting group such as t-butoxycarbonyl, followed by optional deprotection.

Step (i) may be performed using similar conditions to those described for process (a) above.

Compounds of formula (II) wherein m is 0 may be prepared by a deprotection reaction of a compound of formula (IX) as defined above, followed by an analogous process to

(2002)]. In vivo, H3 receptor agonists inhibit the decrease in nasal airway resistance produced by sympathetic nerve activation [Hey et al, Arzneim-Forsch Drug Res., 48:881-888 (1998)]. Furthermore, H3 receptor antagonists in combination with histamine H1 receptor antagonists reverse the effects of mast cell activation on nasal airway resistance and nasal cavity volume; an index of nasal congestion [McLeed et al, Am. J. Rhinol., 13: 391-399, (1999)]. A combined histamine H1 and H3 receptor antagonist, such as the series described herein, would be effective in the treatment of both the nasal congestion and the sneezing, itching and rhinorrhea associated with both seasonal and perennial allergic rhinitis.

10

15

25

Therefore, examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial anti-inflammatory effects include diseases of the respiratory tract such as asthma (including allergic and non-allergic), allergic rhinitis, sinusitis, bronchitis (including chronic bronchitis), bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Other examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial effects include diseases of the gastrointestinal tract such as intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.

Dual histamine H1 and H3 antagonists of the present invention may also be of use in the treatment of sleep/wake disorders, arousal/vigilance disorders, migraine, dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, depression, manic disorders, bipolar disorders and diabetes.

Diseases of principal interest for a dual histamine H1 and H3 antagonist include asthma, COPD and inflammatory diseases of the upper respiratory tract involving seasonal and perennial allergic rhinitis, non-allergic rhinitis, and the specific symptoms associated with these diseases including nasal congestion, rhinorrhoea, sneezing, cough and itching (pruritis) of eyes, ears, nose and throat. Other diseases of principal interest include cough, chronic urticaria, allergic conjunctivitis, nasal polyposis, sinusitis, psoriasis, eczema and allergic dermatoses (including urticaria, atopic dermatitis, contact dermatitis, drug rashes and insect bites).

Diseases of principal interest include asthma, COPD, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

Preferred diseases of principal interest include asthma, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

Further diseases also of principal interest include inflammatory diseases of the gastrointestinal tract such as inflammatory bowel disease.

Thus the invention also provides a dual histamine H1 and H3 antagonist compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular allergic

Preferred dual histamine H1 and H3 antagonist compounds of formula (I) are those wherein

R<sup>1</sup> represents aryl (eg. phenyl, naphthyl or tetrahydronaphthyl) or heteroaryl (eg.

15 benzofuranyl, indolyl or quinolinyl);

R<sup>1</sup> is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; -C<sub>1-6</sub> alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR<sup>15</sup> (eg. COOMe); -C<sub>1-6</sub> alkoxy (eg. methoxy) optionally substituted by COOR<sup>15</sup> (eg. COOMe); C<sub>1-6</sub> alkenyl (eg. ethenyl); NR<sup>15</sup>R<sup>16</sup> (eg. N(Me)<sub>2</sub>); or

20 C<sub>1-6</sub> alkylthio (eg. -S-ethyl) groups;

Z is a bond or CO;

m is 0 or 2;

n is 0;

r is 0;

25 p is 1.

10

R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>11</sup>R<sup>12</sup>;

a represents 3; and

NR<sup>11</sup>R<sup>12</sup> represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C<sub>1-8</sub> alkyl (eg. methyl or ethyl), more preferably piperidinyl substituted by one or two methyl or ethyl groups.

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.

40

30

35

When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.

- Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents (such as corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide) or NSAIDs (eg. sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, lipoxygenase inhibitors, chemokine antagonists (e.g CCR3, CCR1, CCR2, CXCR1,
- CXCR2), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists)) or beta adrenergic agents (such as salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof), or sympathomimetics (e.g pseudoephedrine or oxymetazoline), or other antagonists at the histamine receptor (e.g H4), or cholinesterase inhibitors, or cholinergic antagonists, or antiinfective agents (eg. antibiotics, antivirals).
  - A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, topical, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

30

- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents,

PCT/EP2003/011423 WO 2004/035556

non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

#### 30 **Description 1**

5

10

15

20

25

35

40

4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert -butyl ester (D1)

To a solution of 4-(3-(piperidin-1-yl)propoxy)benzaldehyde (WO 02/12214 A2) (1.90g, 7.68mmol) in dichloromethane (25ml) was added 1-N tert butoxy carbonyl piperazine (1.57g, 8.45mmol) followed by acetic acid (1ml), and the reaction stirred for 1 hour at room temperature, then treated with sodium triacetoxy borohydride (2g, 9.61mmol) and stirred for 16 hours at room temperature. The reaction was then diluted with saturated sodium bicarbonate solution and extracted with dichloromethane. The dichloromethane was then washed sequentially with water and brine, dried over anhydrous sodium sulfate and evaporated in vacuo to yield a residue which was purified using silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title compound (1.586g, 50%); MS (ES+), m/e 418 [M+H]<sup>+</sup>.

#### Description 2

# 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine trihydrochloride (D2)

To a solution of 4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester (D1) (1.576g, 3.76mmol) in a (1:1) mixture of dichloromethane and methanol (20ml) was added a 1M solution of hydrogen chloride in diethyl ether (20ml) and the reaction stirred for 5 hours at room temperature. The solvent was then evaporated *in vacuo* and the resulting residue triturated with diethyl ether to afford the title compound (1.5g, 93%); MS (ES+), m/e 318 [M+H]<sup>†</sup>.

10

#### **Description 3**

4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane-1-carboxylic acid *tert*-butyl ester (D3)




The title compound (D3) was prepared from [1,4]diazepane-1-carboxylic acid *tert*-butyl ester using the method of Description 1 (D1).

MS(ES+) m/e 432 [M+H]<sup>+</sup>.

## **Description 4**

20 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4)



4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane-1-carboxylic acid *tert*-butyl ester (D3) (2.27g, 5.27mmol) was dissolved in dichloromethane (10ml), treated with trifluoroacetic acid (5ml) and stirred at room temperature under argon for 2 hours. The solvent was removed *in vacuo* and the residue dissolved in methanol and passed down an SCX column (10g) eluting with methanol followed by 0.88 ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (1.57g).

MS(ES+) m/e 332 [M+H]<sup>+</sup>.

30

25

#### **Description 5**

## 4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D5)

4-Hydroxybenzaldehyde (2.0g, 16.4mmol) was dissolved in tetrahydrofuran (20ml) and treated with 4-hydroxy-piperidine-1-carboxylic acid *tert*-butyl ester (4.1g, 20.5mmol) and

by column chromatography on silica eluting with 4-1 hexane – ethyl acetate to afford the title compound as a colourless viscous oil (3.8 g) MS (ES+) m/e 355 [M+H]<sup>+</sup>.

#### 5 Description 10

4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D10)

A mixture of 4-[4-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D9) (4.0 g; 11.3 mM), piperidine (2.23 ml; 2 eq), potassium carbonate (3.73 g; 2.4 eq)

and potassium iodide (3.74 g; 2 eq) in butan-2-one (100 ml) was heated at reflux for 3 days. The mixture was allowed to cool to room temperature, filtered and evaporated to give the title compound as a pale yellow solid (4.6 g)

MS (ES+) m/e 404 [M+H]<sup>+</sup>.

#### 15 Description 11

20

### 1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D11)

A solution of 4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D10) (1.0 g; 2.48 mM) in trifluoroacetic acid (5 ml) was stirred at room temperature for 60 minutes. The resulting mixture was purified on an SCX ion exchange cartridge to afford the title compound as a colourless crystalline solid (0.76 g) MS (ES+) m/e 304 [M+H]<sup>+</sup>.

#### **Description 12**

#### 4-(3-Hydroxy-phenyl)-piperazine-1-carboxyllc acid tert-butyl ester (D12)

Prepared from 3-piperazin-1-yl-phenol (Chem. Pharm. Bull. <u>49</u>(10), 1314 (2001)) using the same method described in Description 8 (D8).

MS (ES+) m/e 279 [M+H]<sup>+</sup>.

#### **Description 13**

4-[3-(3-Chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D13)
Prepared from 4-(3-hydroxy-phenyl)-piperazine-1-carboxylic acid *tert*-butyl ester (D12)
using the same method described in Description 9 (D9).

MS (ES+) m/e 355 [M+H]<sup>+</sup>.

#### 35 Description 14

4-[3-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D14)

Prepared from 4-[3-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D13) using the same method described in Description 10 (D10).

40 MS (ES+) m/e 404 [M+H]+.

#### **Description 15**

## 1-[3-(3-PiperidIn-1-yl-propoxy)-phenyl]-piperazine (D15)

butyl ester (D14) using the same method described in Description 11 (D11). MS (ES+) m/e 304 [M+H]+.

5

10

15

### **Description 16**

#### 4-Bromo-1-methyl-1H-indole (D16)



A solution of 4-bromo-1H-indole (6.7 g) in tetrahydrofuran (75 ml) was treated with sodium hydride (1.24 g) and stirred for 0.5 h at room temperature. The resulting suspension was treated with a solution of iodomethane (2.34 ml) in tetrahydrofuran (35 ml) at 0°C and allowed to warm to room temperature over 1h, whilst stirring. The reaction mixture was poured onto water and partitioned between dichloromethane and water. The organic phase was dried over (MgSO<sub>4</sub>) and concentrated in vacuo to afford the title and the become control of the contro compound (7.2 g). TLC Silica (cyclohexane-ethyl acetate [1:1]), Rf = 0.55.

## **Description 17**

## 4-Bromo-1-methyl-1H-indole-3-carboxylic acid (D17)

A solution of 4-bromo-1-methyl-1H-indole (D16) (7.0 g) in tetrahydrofuran (50 ml) was 20 treated with a solution of trifluoroacetic anhydride (5.65 ml) in tetrahydrofuran (20 ml) at 0°C. The reaction mixture was allowed to warm to room temperature over 6 h, whilst stirring. The reaction mixture was concentrated in vacuo and then re-suspended in ethanol (25 ml). The solution was treated with 5N sodium hydroxide solution (50 ml) and 25 heated under reflux for 18 h. The reaction mixture was washed with diethyl ether and the aqueous phase acidified with 5N hydrochloric acid solution. The precipitate was filtered, o directadores respectados de casa de constitución de casa de c washed with water and concentrated in vacuo to afford the title compound (4.88 g). TLC, Silica (cyclohexane-ethyl acetate-acetic acid [3:1:0.1]), Rf = 0.35.

#### 30 **Descriptions 18-23**

Descriptions 18-23 were prepared using analogous methods to Example 76b by substituting 2-methylpiperidine with the appropriate amine.

Description	Churchine	1 <b>5 7</b>	
Description	Structure	RT (min)	Mass ion (M+H) <sup>+</sup>
			,

_				
	18		1.64	332
	19	CH <sub>3</sub> NH	0.65	304
no com a traditional antica and a material source and a soul	20		1.77	346
	21	NH CH <sub>3</sub>	1.45	318
i de el describigio de describigio de describigio de describigio de describigio de de describigio de de describigio de de describigio de de describigio de describigio de describigio de describigio de de describigio de describigio de describigio de describigio de de describigio de describigio de describigio de de describigio de de describigio de desc	ALC ON THE RESIDENCE OF THE SECOND OF THE SE	H <sub>3</sub> C N N N N N N N N N N N N N N N N N N N	1.57	332
	23	H <sub>2</sub> C NH	1.61	318

## **Descriptions 24-32**

Descriptions 24-32 were prepared by analogous methods to those indicated in the below table:

5

TO STATE OF PROPERTY AND A STATE OF THE STATE OF THE

Description	Name	Prepared analogously to	RT (min)
24	1,1-Dimethylethyl 4-(2-naphthalenyl)- 1-piperazinecarboxylate	E229a from known starting materials	3.74
25	1,1-Dimethylethyl 4-(4-quinolinyl)-1- piperazinecarboxylate and 1,1- dimethylethyl 4-(3-quinolinyl)-1- piperazinecarboxylate (1:1)	E229a from known starting materials	2.18 & 3.02

26	1-(2-Naphthalenyl)piperazine	E229b from known starting materials	2.00
27	4-(1-Piperazinyl)quinoline and 3-(1-piperazinyl)quinoline (1:1)	E229b from D25	1.18
28	3-{[4-(2-Naphthalenyl)-1- piperazinyl]methyl}phenol	E229c from D24	2.39
29	3-{[4-(1-Naphthalenyl)-1- piperazinyl]methyl}phenol	E229c from D26	2.41
30	4-{[4-(8-Quinolinyl)-1- piperazinyl]methyl}phenol	E229c from E229b	1.78
31 520 07 (1500) (1600)	4-{[4-(4-Quinolinyl)-1-	E229c from D27	1.91
32	4-{[4-(1-Naphthalenyl)-1- piperazinyl]methyl}phenol	E229c from D26	2.46

# **Descriptions 33-42**

Descriptions 33-42 were prepared by analogous methods to those indicated in the below table:

5

	Description	Name	Prepared analogously to	RT (min)
der vis lindsgereitet sind eintergetweitet der Frei-	33	2-Methyl-4-[4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl)-1- piperazinyl]quinoline	E237a from known starting materials	2.20
	34	2-Methyl-4-[4-(2-{3- [(phenylmethyl)oxy]phenyl}ethyl)-1- piperazinyl]quinoline	E237a from known starting materials	2.11
	35	1-(1-Naphthalenyl)-4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.91
	36	1-(1-Naphthalenyl)-4-(2-{3- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.82

37	1-Phenyl-4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.55
38	4-{2-[4-(2-Methyl-4-quinolinyl)-1-		1.69
39	3-{2-[4-(2-Methyl-4-quinolinyl)-1- piperazinyl]ethyl}phenol	E237b from D34	4.56
40	4-{2-[4-(1-Naphthalenyl)-1- piperazinyl]ethyl}phenol	E237b from D35	2.28
41	3-{2-[4-(1-Naphthalenyl)-1- piperazinyl]ethyl}phenol	E237b from D36	2.32
42	4-[2-(4-Phenyl-1- piperazinyl)ethyl]phenol	E237b from D37	2.02

#### **Description 43**

## 3-Bromo-4-ethyl-benzoic acid (D43)



To a mixture of conc. HNO<sub>3</sub> (66 mL), glacial AcOH (300 mL) and water (50 mL), 4-ethylbenzoic acid (15 g) was added, stirring vigorously, before treating with bromine (5.67 mL). Finally a solution of AgNO<sub>3</sub> (16.97 g) in water (50 mL) was added dropwise and the mixture was stirred vigorously for 2 h. The precipitate was collected by filtration, washed well with water, before being extracted with hot, saturated K<sub>2</sub>CO<sub>3</sub> solution, and then treated with charcoal. The hot solution was filtered through kieselguhr and the solution was acidified to pH1 using conc. HCl. The resulting white precipitate was collected by filtration and dried in the vacuum oven overnight at 60 °C to afford the title compound (19.46 g).

NMR (CDCl<sub>3</sub>) δ 1.26 (3H, t), 2.83 (2H, q), 7.34 (1H, d), 7.97 (1H, dd), 8.27 (1H, dd)

## 15

#### **Description 44**

#### Methyl 3-bromo-4-ethyl-benzoate (D44)



3-Bromo-4-ethyl-benzoic acid (D43) (19.40 g) was dissolved in MeOH (200 mL) and then treated with conc. H<sub>2</sub>SO<sub>4</sub> (1 mL). The mixture was heated at reflux overnight, and then concentrated under reduced pressure. The residue was partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub> solution, extracting again with EtOAc. The combined

extracts were then washed with brine, dried (MgSO<sub>4</sub>). The solvent was evaporated in vacuo to afford the title compound (15.8 g). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.24 (3H, t), 2.79 (2H, q), 3.91 (3H, s), 7.29 (1H, d), 7.89 (1H, dd), 8.19 (1H, d).

#### **Description 45**

10

15

Methyl 3-cyano-4-ethyl-benzoate (D45)

Methyl 3 bromo 4 ethyl benzoate (D44) (5 g) in NMP (180 mL) was treated with copper (I) cyanide (3.69 g). The mixture was then heated at reflux for 5 h, under argon. After cooling to 20 °C the reaction mixture was diluted with water, then filtered through kieselguhr, washing well with water and EtOAc. The organic layer was washed with water, brine and dried over MgSO<sub>4</sub>. The solvent was evaporated to dryness in vacuo and the residue was purified by chromatography on silica eluting with EtOAc- Hexane (1:9) to give the title compound (1.9 g) <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.33 (3H, t), 2.94 (2H, q), 3.94 (3H, s), 7.43 (1H, d), 8.17 (1H, dd), 8.28 (1H, d).

## **Description 46**

3-Cyano-4-ethyl benzoic acid (D46)

Methyl 3-cyano-4-ethyl-benzoate (D45) (1.92 g) was dissolved in MeOH (50 mL) before adding 1M NaOH solution (15.24 mL) and stirring the resulting mixture overnight at room temperature, under argon. The reaction mixture was diluted with water, and extracted with EtOAc. The aqueous layer was acidified to pH1 using 2M HCl before extracting with EtOAc. The combined extracts were washed with brine, dried over MgSO₄ and the 25 solvent evaporated to dryness in vacuo to afford the title compound (1.63 g). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.35 (3H, t), 2.97 (2H, q), 7.49 (1H, d), 8.24 (1H, dd), 8.36 (1H, d).

Analysis of the Examples was performed as follows:

LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID) eluting with 0.1% formic acid and 0.01M ammonium acetate in water (solvent A) and 30 0.05% formic acid and 5% water in acetonitrile (solvent B), using the following elution gradient 0.0-7min 0%B, 0.7-4.2 min 100%B, 4.2-5.3 min 0%B, 5.3-5.5min 0%B at a flow rate of 3 mL/min. The mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES-ve).

	methanone (E3)		
	1-(3,5-Dichloro-phenyl)-1-{4-[4-(3-	3,5-	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	dichlorobenzoic	491/493 [M+H]+
	yl}-methanone (E4)	acid	
	1-(4-Bromo-3-methyl-phenyl)-1-{4-[4-(3-	3-methyl, 4-bromo	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	benzoic acid	515/517 [M+H]+
	yl}-methanone (E5)		
	1-(2-Methoxy-phenyl)-1-{4-[4-(3-piperidin-	2-methoxy benzoic	MS (ES+) m/e
LE CONTRACTO DE LA CONTRACTO D	1-yl-propoxy)-benzyl]-piperazin-1-yl}-	.acid	452.[M+H]+
	methanone (E6)		
	1-(3,4-Dichloro-phenyl)-1-(4-[4-(3-	3,4-dichloro	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	benzoic acid	491/493/495
	yl}-methanone (E7)		[M+H] <sup>+</sup>
•	4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-	4-cyano benzoic	MS (ES+) m/e
	benzyl]-piperazin-1-yl}-methanoyl)-	acid	447 [M+H] <sup>+</sup>
•	benzonitrile (E8)		
	1-(4-Fluoro-phenyl)-1-{4-[4-(3-piperidin-1-	4-fluoro benzoic	MS (ES+) m/e
	yl-propoxy)-benzyl]-piperazin-1-yl}-	acid	440 [M+H]+
	methanone (E9)	<u> </u>	
	1-(4-Bromo-phenyl)-1-{4-[4-(3-piperidin-1-	4-bromo benzoic	MS (ES+) m/e
	yl-propoxy)-benzyl]-piperazin-1-yl}-	acid	500/502 [M+H] <sup>+</sup>
	methanone (E10)		
	1-Benzofuran-2-yl-1-{4-[4-(3-piperidin-1-yl-	2-benzofuran	MS (ES+) m/e
The contraction of the desired specific con-	propoxy)-benzyl]-piperazin-1-yl}-	carboxylic acid	462 [M+H]+
•	methanone (E11)		

## Example 12

1-Benzo[1,3]dioxol-5-yl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E12)

5

1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in dichloromethane (5ml) and treated sequentially with benzo[1,3]dioxole-5-carboxylic acid (125mg, 0.75mmol), 1,3-dicyclohexylcarbodiimide (155mg, 0.75mmol) and 1-hydroxybenzotriazole hydrate (101mg, 0.75mmol). The mixture was allowed to stir at room temperature under argon for 12 hours, diluted with methanol and passed down an SCX ion exchange column (2g) eluting with methanol followed by 0.880

ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (127mg). MS(ES+) m/e 480 [M+H]+.

#### Examples 13-15

5 Examples 13-15 (E13-E15) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table.

Example	Carboxyllc acid	Mass Spectrum
1-Phenyl-1-{4-[4-(3-	Benzoic acid	MS(ES+) m/e 436
piperidin-1-yl-		[M+H] <sup>+</sup>
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-	n.	
methanone (E13)		
1-Naphthalen-2-yl-1-	Naphthalene-2-	MS(ES+) m/e 486
{4-[4-(3-piperidin-1-yl-	carboxylic acid	[M+H] <sup>+</sup>
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		·
methanone (E14)		
1-(3,5-Dichloro-	3,5-Dichloro-benzoic	MS(ES+) m/e 505
phenyl)-1-{4-[4-(3-	acid	[M+H] <sup>+</sup>
piperidin-1-yl-	'	
propoxy)-benzyl]-	·	
[1,4]diazepan-1-yl}-		
methanone (E15)		

## 10 Examples 16-23

AND AND ARREST AND ARREST AND ARREST AND ARREST ARR


Examples 16-23 (E16-E23) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of .880

ammonia/methanol/dichloromethane (0.5:4.5:95).

Example	Carboxylic acid	Mass Spectrum
1-(4-Bromo-3-methyl-	4-Bromo-3-methyl-	MS(ES+) m/e 529
phenyl)-1-{4-[4-(3-	benzoic acid	[M+H]*
piperidin-1-yl-		
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E16)		
1-(2-Methoxy-phenyl)-	2-Methoxy-benzoic	MS(ES+) m/e 466
1-{4-[4-(3-piperidin-1-	acid	[M+H] <sup>+</sup>

yl-propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E17)		
4-(1-{4-[4-(3-Piperidin-	4-Cyano-benzoic acid	MS(ES+) m/e 461
1-yl-propoxy)-benzyl]-		[M+H] <sup>†</sup>
[1,4]diazepan-1-yl}-		
methanoyl)-	potable par income entre care, transfer le le come centrale abrestant les equelles.	ma. Mais teles, in principle, in principle services in season expensive services.
benzonitrile (E18)		
1-(4-Fluoro-phenyl)-1-	4-Fluoro-benzoic acid	MS(ES+) m/e 454
{4-[4-(3-piperidin-1-yl-		[M+H] <sup>+</sup>
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E19)		
1-(4-Bromo-phenyl)-1-	4-Bromo-benzoic acid	MS(ES+) m/e 515
{4-[4-(3-piperidin-1-yl-		[M+H] <sup>+</sup>
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E20)		
1-Benzofuran-2-yl-1-	Benzofuran-2-	MS(ES+) m/e 476
{4-[4-(3-piperidin-1-yl-	carboxylic acid	[M+H] <sup>†</sup>
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-	år tillste på synnarent miller, tri hiller i en nynasterflere hannfarr, en nyn her	and the second of the second o
methanone (E21)		
1-(3,4-Dichloro-	3,4-Dichloro-benzoic	MS(ES+) m/e 505
phenyl)-1-{4-[4-(3-	acid	[M+H] <sup>+</sup>
piperidin-1-yl-		
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E22)		
1-Cyclopropyl-1-{4-[4-	Cyclopropane	MS(ES+) m/e 400
(3-piperidin-1-yl-	carboxylic acid	[M+H]*
propoxy)-benzyl]-	•	-
[1,4]diazepan-1-yl}-		
methanone (E23)		
	methanone (E17) 4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanoyl)- benzonitrile (E18) 1-(4-Fluoro-phenyl)-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanone (E19) 1-(4-Bromo-phenyl)-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanone (E20) 1-Benzofuran-2-yl-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanone (E21) 1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanone (E22) 1-Cyclopropyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl-propoxy)-benzyl]-	[1,4]diazepan-1-yl}- methanone (E17)  4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanoyl)- benzonitrile (E18)  1-(4-Fluoro-phenyl)-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl}- methanone (E19)  1-(4-Bromo-phenyl)-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E20)  1-Benzofuran-2-yl-1- {4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E21)  1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E22)  1-Cyclopropyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E22)  1-Cyclopropyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E22)  1-Cyclopropyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepan-1-yl]- methanone (E22)

Example 24
1-Cyclopentyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}methanone (E24)



1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in dichloromethane (5ml), treated with cyclopentyl acid chloride (80mg, 0.60mmol), potassium carbonate (83mg, 0.60mmol) and allowed to stir at room
temperature under argon for 12 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (56mg). MS(ES+) *m/e* 428 [M+H]<sup>+</sup>.

### 10 Example 25

1-Benzenesulfonyl-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (E25)



1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in 2-butanone (5ml), treated with benzene sulfonyl chloride (57mg, 0.32mmol) and allowed to stir at room temperature under argon for 2 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (91mg). MS(ES+) m/e 472 [M+H]<sup>+</sup>.

#### 1000

20

25

Examples 26-28 (E26-E28) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table.

Example	Sulfonyl Chloride	Mass Spectrum
1-(Naphthalene-2-sulfonyl)-4-[4-(3- piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepane (E26)	Naphthalene-2- sulfonyl chloride	MS(ES+) m/e 522 [M+H] <sup>+</sup>
1-(4-Fluoro-benzenesulfonyl)-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepane (E27)	4-Fluoro- benzenesulfonyl chloride	MS(ES+) m/e 490 [M+H] <sup>+</sup>
1-(4-Bromo-benzenesulfonyl)-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-	4-Bromo- benzenesulfonyl	MS(ES+) m/e 552 [M+H] <sup>+</sup>

[1,4]diazepane (E28)	chloride	
[[1,4]diazeparte (L20)	CHIOHAE	

### Examples 29-31

Examples 29-31 (E29-E31) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride

for the appropriate sulfonyl chloride indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of .880 ammonia/methanol/dichloromethane (0.5:4.5:95).

Example	Sulfonyl Chloride	Mass Spectrum
1-(3,5-Dichloro-benzenesulfonyl)-	3,5-Dichloro-	MS(ES+) m/e 540
4-[4-(3-piperidin-1-yl-propoxy)-	benzenesulfonyl	[M+H] <sup>+</sup>
benzyl]-[1,4]diazepane (E29)	chloride	
1-(3,4-Dichloro-benzenesulfonyl)-	3,4-Dichloro-	MS(ES+) m/e 540
4-[4-(3-piperidin-1-yl-propoxy)-	benzenesulfonyl	[M+H] <sup>+</sup>
benzyi]-[1,4]diazepane (E30)	chloride	
4-{4-[4-(3-Piperidin-1-yl-propoxy)-	4-Cyano-	MS(ES+) m/e 497
benzyl]-[1,4]diazepane-1-	benzenesulfonyl	[M+H] <sup>+</sup>
sulfonyl}-benzonitrile (E31)	chloride	

#### 10 Example 32

1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32)

The title compound (E32) was prepared from 4-{4-[4-(1-phenyl-methanoyl)-piperazin-1-ylmethyl]-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester (D7) using the method described in Description 4 (D4). MS(ES+) m/e 380 [M+H]\*.

## Example 33


20 **(E33)** 

The title compound (E33) was prepared from 1-phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) and acetone using the method described in Description 1 (D1). MS(ES+) m/e 422 [M+H]<sup>+</sup>.

5

#### Example 34

1-(4-{4-[1-(2-Methoxy-ethyl)-piperidin-4-yloxy]-benzyl}-piperazin-1-yl)-1-phenyl-methanone (E34)



10

25

unication from the first action of the selection of the s

1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) (150mg, 0.40mmol) was dissolved in 2-butanone and treated with 1-chloro-2-methoxy-ethane (0.08ml, 0.80mmol), potassium carbonate (132mg, 0.96mmol) and potassium iodide (159mg, 0.96mmol). The reaction mixture was heated under reflux for 24 hours. The mixture was allowed to cool to room temperature, acidified by the addition of glacial acetic acid and passed down an SCX ion exchange column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (76mg). MS(ES+) *m/e* 438 [M+H]<sup>+</sup>.

## 20 Examples 35-37

Examples 35-37 (E35-E37) were prepared in accordance with the following general synthesis:

The appropriate acid chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyi]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

	Acid Chloride	Mass Spectrum
1-Cyclopropyl-1-{4-[4-(3-piperidin-	Cyclopropane	MS (ES+) m/e 372

{	1-yl-propoxy)-phenyl]-piperazin-1- yl}-methanone (E35)	carbonyl chloride	[M+H] <sup>+</sup> .
r	1-Phenyl-1*(4-{4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanone (E36)	Benzoyl chloride	-MS (ES+) m/e 408 [M+H] <sup>+</sup> .
	1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanone (E37)	3,4- Dichlorobenzoyl chloride	MS (ES+) m/e 477 [M+H] <sup>+</sup> .

## Examples 38-39

TO PROGRESS OF THE PARTY OF THE

16万分的工具有整理管理。1666年20万分数的1967年1964年16

TO POST PROPERTY WITH A PARTY OF THE PROPERTY AND A PA

15

Examples 38-39 (E38-E39) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 36 and 37, respectively.

Example	Mass Spectrum
1-Phenyl-1-{4-[3-(3-piperidin-1-yl-propoxy)-	MS (ES+) m/e 408 [M+H] <sup>+</sup> .
phenyl]-piperazin-1-yl}-methanone (E38)	
1-(3,4-Dichloro-phenyl)-1-(4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 477 [M+H]
propoxy)-phenyl]-piperazin-1-yl}-methanone	
(E39)	

## Examples 40-42

Examples 40-42 (E40-E42) were prepared in accordance with the following general synthesis:

The appropriate sulphonyl chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yi-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

Example	Sulfonyl Chloride	Mass Spectrum
1-Methanesulphonyl-4-[4-(3-piperidin-1-yl-	Methane sulfonyl	MS (ES+) m/e 382
propoxy)-phenyl]-piperazine (E40)	chloride	[M+H] <sup>+</sup> .
1-Benzenesulphonyl-4-[4-(3-piperidin-1-yl-	Benzene sulfonyl	MS (ES+) m/e 444
propoxy)-phenyl]-piperazine (E41)	chloride	[M+H] <sup>+</sup> .
1-(3,4-Dichloro benzenesulphonyl)-4-[4-(3-	3,4-	MS (ES+) m/e 513
piperidin-1-yl-propoxy)-phenyl]-piperazine	Dichlorobenzene	[M+H] <sup>+</sup> .
(E42)	sulfonyl chloride	<u> </u>

## Examples 43-45

Examples 43-45 (E43-E45) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 40, 41 and 42, respectively.

Example	Mass Spectrum
1-Methanesulphonyl-4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 382
propoxy)-phenyl]-piperazine (E43)	[M+H] <sup>+</sup> .
1-Benzenesulphonyl-4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 444
propoxy)-phenyl]-piperazine (E44)	[M+H] <sup>+</sup> .
1-(3,4-Dichloro benzenesulphonyl)-4-[3-(3-	MS (ES+) m/e 513
piperidin-1-yl-propoxy)-phenyl]-piperazine (E45)	[M+H] <sup>+</sup> .

5

na kanana ang kanana a

#### Examples 46-47

Examples 46-47 (E46-E47) were prepared in accordance with the following general synthesis:

The appropriate isocyanate (1.1 eq) was added to 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

Example	Isocyanate	Mass Spectrum
4-[4-(3-Piperidin-1-yl-propoxy)-	Isocyanatobenzene	MS (ES+) m/e
phenyl] piperazine-1-carboxylic acid phenylamide (E46)	e delper en egisten (den 1905), som egiste til en en en i stere en	423 [M+H]*.
4-[4-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine-1-carboxylic acid	3,4-Dichloro isocyanato benzene	MS (ES+) m/e 492 [M+H]+.
(3,4-dichloro-phenyl)-amide (E47)	isocyanato benzene	402 [Wittig .

15

## Example 48

4-[4-(3-PiperidIn-1-yl-propoxy)-phenyl] plperazine-1-carboxylic acid cyclopropylamide (E48)

20

To a solution of 1-[4-(3-plpendin-1-yl-propoxy)-phenyl]-piperazine (DT1) (150 mg; 0.49 mM) in dry dichloromethane (3 ml) was added drop wise a 20% solution of phosgene in toluene (0.5 ml; ~2 eq) and the resulting mixture stirred for 1 hour. The solvent was

temoved by evaporation and the resulting white powder dissolved in dry dichloromethane (4 ml). Triethylamine (0.14 ml: 2 eq) was added followed by cyclopropylamine (0.1 ml; 3 eq) and the mixture stirred for 18 hours. The solvent was removed by evaporation in vacuo and the residue purified on a silica column eluting with 3% methanol in dichloromethane to afford the title compound as a white solid (155 mg) MS (ES+) m/e 387 [M+H]+.

#### Examples 49-50

5

Examples 49-50 (E49-E50) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]piperazine (D15) using the same procedure as described in Examples 46 and 47, 10 respectively.

Example	Mass Spectrum
4-[3-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine-1-carboxylic acid phenylamide (E49)	MS (ES+) m/e 423 [M+H] <sup>+</sup> .
4=[3=(3=Piperidin-1=yl-propoxy)-phenyl]	MS (ES+) m/e 492
piperazine-1-carboxylic acid (3,4-dichloro-	[M+H] <sup>+</sup> .
phenyl)-amide (E50)	

#### Example 51

20

25

1-(3,4-Dichloro-phenyl)-4-[4-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine (E51) 15

Tris(dibenzylidineacetone) di palladium (0) (5 mol%; 23 mg) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (150 mg; 0.49 mmol), 3,4-dichloro bromo benzene (160 mg; 1.2 eq), sodium tert-butoxide (71 mg; 1.1 eq) and racemic 2,2'bis(diphenylphosphino)-1,1'-binaphthyl (7.5 mol%; 24 mg) in dry toluene (3ml). The S PORTE DE PROPERTIE DE LE PRES DE PROPERTIE DE LA FRANCE resulting mixture was heated at reflux under argon for 18 hours. The reaction was allowed to cool to room temperature and diluted with ethyl acetate (10 ml). The resulting solids were removed by filtration and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica eluting with 3% methanol in dichloromethane to afford the title compound as a buff solid (45 mg) MS (ES+) m/e 448 [M+H]+.

#### Example 52

1-(3,4-Dichloro-phenyl)-4-[3-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine (E52) 30

The title compound (E52) was prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same method as described in Example 51 (E51). MS (ES+) m/e 448 [M+H]<sup>+</sup>.

#### Example 53

etti katikati katikati katikati katikat katika k

5-Fluoro-1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1*H*-indole (E53)

A solution of 5-fluoro-1-methyl-1*H*-indole-3-carboxylic acid [WO 0071537 A1] (35 mg) and 1-(4-{[3-(1-plperidinyl)propyl]oxy}phenyl)piperazine (D11) (50 mg) in dichloromethane (1ml) was treated with benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (94.4 mg) and heated in a microwave (CEM<sup>™</sup> Discover microwave) at 120°C for 5 min. The reaction mixture was concentrated *in vacuo* and purified on a SCX cartridge (2g) eluting with methanol-aqueous ammonia (10:1) followed by mass directed auto preparative HPLC to give *the title compound* (12 mg). LCMS RT = 2.49 min, 478 (M+H)<sup>+</sup>

#### Examples 54-61

SECTION AND CONTRACTOR OF THE PROPERTY OF

TO CONTROL OF CONTROL OF CONTROL OF THE SECOND CONTROL OF THE CONT

The following compounds were prepared in an analogous manner to the process described for E53 from D11 and a known appropriate acid, with the exception of Example 57 which was prepared from D11 and D17.

Example	Structure	RT (min)	Mass ion (M+H) <sup>+</sup>
54		2.37	448 450
55 Пинасторический	Note Made and a second state of the second sta	2.26	464

	56		2.41	478
		CH COH		
	57		2.40	539 541
	58		2.32	474
Filo omanikanomo uno omanikanomo kaja k	ankii ari iraabaasaanyare	CH, SH, SH, SH, SH, SH, SH, SH, SH, SH, S	may, will support to the original support to the su	- The Marie of the Selection
	59		2.56	539 541
		BT CHA		
	60		2.54	546
		OT NOT OH		
TO STATE THE PROPERTY OF THE STATE OF THE ST	antition in the desirement		2.80	536

## Example 62

(1-Methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1*H*-indol-2-yl)acetic acid (E62)

Α solution of ethyl (1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1piperazinyl]carbonyl}-1H-indol-2-yl)acetate (E60) [54 mg] in methanol [6 ml] and water [0.8 ml] was treated with 2N sodium hydroxide [0.46 ml] and was heated under reflux for 2 h. The reaction mixture was quenched with hydrochloric acid [10 ml] at room temperature. The reaction mixture was concentrated in vacuo and partitioned between concentrated in vacuo to give the organic phase was dried and concentrated in vacuo to give the title compound (20 mg). LCMS RT = 2.35 min, 518 (M+H)\*

#### Example 63

20

25

35

10 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate (E63)

E63a: 4-[4-(1-Naphthoyl)piperazin-1-yl]phenol

15 To a stirring mixture of 4-(1-piperazinyl)phenol (5.54 g) and triethylamine (10.83 ml) in dichloromethane (140 ml) was added dropwise, 1-naphthalenecarbonyl chloride (9.83 ml). The resulting reaction mixture was stirred under a nitrogen atmosphere for 3 h. The mixture was partitioned between dichloromethane and water and the organic phase was washed with saturated brine, dried (MgSO<sub>4</sub>) and evaporated to dryness. The residue was suspended in 6:4 tetrahydrofuran-methanol (370 ml) and treated with a saturated solution of potassium carbonate in methanol (45 ml). The mixture was stirred at room temperature under a nitrogen atmosphere for 20 h. The solvent was evaporated and the residue was partitioned between dichloromethane and water. The organic phase was washed with saturated brine, dried (MgSO<sub>4</sub>) and evaporated to give an oil (15.5 g), part of which (14.5 g) was purified by chromatography on a silica SPE bond elut cartridge eluting with 10% -80% ethyl acetate - cyclohexane gradient to give the title compound (8.9g). LCMS RT = 2.97 min.

# E63b: 1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine

Was prepared from 4-[4-(1-naphthoyl)piperazin-1-yl]phenol (E63a) and 1-bromo-3-30 chloropropane using the same method described in Description 9 LCMS RT = 3.59 min

## E63c: 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate

1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (E63b) (27 mg) piperidine (0.033 ml), potassium carbonate (46 mg), potassium iodide (56 mg)in 2-butanone (2 ml) was heated to reflux for 36 h. The solvent was removed at room temperature by a stream of nitrogen gas. The residue was dissolved in water and dichloromethane. The organic layer was separated, concentrated and purified by mass directed preparative HPLC to give the title compound (23 mg). LCMS RT = 2.15 min, ES+ve m/z 458 (M+H)<sup>+</sup>.

## Examples 64-75

Examples 64-75 were prepared in an array format using the same method described in Example 63c from 1-[4-(3-chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (0.067 mmol), the appropriate secondary amine (5.0 eq), potassium carbonate (5.0 eq), and potassium iodide (5.0 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as TFA salts.

•	•
,	1)
1	1,

10				
	Example	Structure	RT	Mass
The electric Co. Such a brief is not all the first properties a service in a	A 17 of the American Manager	NOTE THE TRANSPORT AND ARREST CONTRACTOR AND ARREST CONTRACTOR OF A SUPPLEMENTAL PROPERTY OF A SUPPLEMENTAL OF A	(min)	lon
and the state of t		NAME NEED MEDITAL OR WELL EST ON THE SECTION OF THE	SAME TO THE	(M+H) <sup>+</sup>
	64		2.76	500
		F OH		
	65	Ola,	2.63	472
		DH DH		
	66		2.55	476
<ul> <li>Selection description of the selection of th</li></ul>	i Notal sing of the Salas and S	s	wante of more a new	i i norma ne godin bodi kwa ci Makabi
		F OH		
	67	The state of the s	2.27	486
		W.C. P. C.H	,	
	68		2.66	472
		O N CH,		}
		F HOH		
Ł		F OH		

	69		2.58	458
ाका पहिल्ला होतर प्रत्याच्या व्यवस्था स्थापना स्थापना स्थापना स्थापना स्थापना स्थापना स्थापना स्थापना स्थापना	antir ant institutional paints	H <sub>3</sub> C N		
	70	P OH	2.71	485.73
stelleber termenter militar et seines et en	71		2.22	472
		H <sub>3</sub> C N		
,	72	O CH,	2.22	472
	73		2.26	514
. Only the properties and a state of properties and a service of the state of the s	or <b>74</b> 0 orronder	F-FOH	2.35	500/***
	75	OH OH	2.24	486

The following the properties of the companies of the comp

WO 2004/035556 PCT/EP2003/011423

Example 76

00R

5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)propoxylphenyl}piperazin-1-

#### Example 76

10

15

5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1*H*-indole (E76)

5 E76a: 1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate

1,1-Dimethylethyl 4-{4-[(3-chloropropyl)oxy]phenyl}-1-piperazinecarboxylate (D9) (1.6g), was dissolved in 2-butanone (10ml). Potassium carbonate (1.38g) and a catalytic amount of potassium iodide were added, followed by 2-methylpiperidine (0.99g). The mixture was heated at reflux for 72 h under nitrogen. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phases were separated using a hydrophobic frit, combined and evaporated *in vacuo*. The residue was purified on a 100g silica SPE bond elut cartridge, eluting with a gradient of 0% to 20% [0.880 ammonia-methanol (1:9)]-dichloromethane mixtures, to give the title compound (1.66g). LCMS RT= 2.48min.

E76b: 1-(4-{[3-(2-Methyl-1-piperidinyl)propyl]oxy}phenyl)piperazine

1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl) propyl]oxy}phenyl)-1piperazinecarboxylate (E76a) (1.66 g) was dissolved in dry dichloromethane (25 ml) and
stirred under nitrogen. 50% Trifluoroacetic acid in dichloromethane (5ml) was added,
and the mixture was stirred at room temperature for 4 h. Saturated sodium bicarbonate
solution was then added and the mixture was extracted with dichloromethane. The
organic phase was separated using a hydrophobic frit, and evaporated *in vacuo*,
however, most of the product was in the aqueous phase. The product was removed
from the aqueous phase using an OASIS cartridge, washing with water and eluting with
methanol, and further purified using an aminopropyl bond elut cartridge, eluting with
dichloromethane and then SCX cartridge, eluting with 50% [0.880 ammonia-methanol

PCT/EP2003/011423 WO 2004/035556

(1:9)]-dichloromethane to give the title compound (0.94 g). LCMS RT= 1.01min, ES+ve  $m/z = 318 (M+H)^{+}$ 

E76c: 5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1H-indole

A solution of 5-fluoro-1-methyl-1H-indole-3-carboxylic acid (19.3 mg) and O-(1Hbenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) (56mg) in DMF (1 ml) and diisopropylethylamine (0.035 ml) was stirred for 10 min before 1-{4-[3-(2methylpiperidin-1-yl)propoxy]phenyl}piperazine (E76b) (21.3 mg) in DMF (0.5 ml) was added. The mixture was stirred for 18 h and then concentrated under reduced pressure. DI AGADA SASA BIRKA KARAN WARAN BARAN WARAN ARAN ARAN The residue was purified by SPE ion exchange chromatography on an SCX-2 cartridge 10 (1g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), to give the title compound (15 mg) LCMS RT = 2.42 min,

## **Examples 77-224**

ES+ve m/z 493 (M+H)<sup>+</sup>.

Examples 77 to 224 were prepared in an array format in vials using a solution of the appropriate carboxylic acid (0.1 mmol) in DMF (0.5 ml) and a solution of O-(1Hbenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) (0.15mmol) in DMF (0.5 ml) and diisopropylethylamine (0.2 mmol). Each vial was shaken manually and stood for 10 min, before a solution of the appropriate piperazine (selected from D18-D23 or D46 in the case of Example 99) (0.067 mmol) in DMF (0.5 ml) was added to each reaction mixture. The vials were left to stand overnight for approximately 18 h at room temperature. Each solution was then added to the top of a preconditioned SCX-2 SPE cartridge (1g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), into pre-weighed vials. The solutions were evaporated to dryness on the genevac to provide the products (Examples 77-222). Examples 151, 154, 162-171 and 206-222 were further purified by mass directed autopreparative HPLC to provide the products as trifluoroacetate salts.

~	,	٠
-4	ŧ	ı

15

20

Example	Structure	RT (min )	Mass ion (M+H) <sup>+</sup>
77	i H <sub>y</sub> c	2.36	438

CA SCHOOL COLD TO BE SEEDED FOR THE COLD TO SEED OF THE COLD TO SE

AND THE STATE OF T

-	78		2.52	464
	79	H,c H,s	2.55	466
	80 Activit insolvenseems		2.44	452
	81		2.74	484
	82	i Ho	2.52	436
and the first program of the first program was a second	83	Paragraphic Company (Company Company C	2.74	480
	84		2.58	476

		R F	2.22	456
08/80/000 a recognision (80/80/80/80/80/80/80/80/80/80/80/80/80/8	.92		2.23	456
		H,c		
•	93		2.76	464
		CH <sub>3</sub>		
	94		2.24	424
	'			ļ
		OH OH		i i
		\_\\\		: 
	05	9	2.16	460
ZOST BOTH DAST TO COLOR OF SERVICE SERVICES AND A SERVICE SERVICES.	95	The second secon	2.16	468
		l o C s		
		CH,		
		8	4.07	460
	96		1.87	463
	,	H <sub>C</sub>		
				1
		P	1.00	463
	97		1.96	463
•				
STREET,	a national consequences	AND THE PROPERTY OF THE PROPER	constitutions	Lagrant Service ( & Service Carol )
	98		1.85	467
		ρ H <sub>s</sub> c N ch,		
	-	<u> </u>	0.44	464
	99		2.11	461
		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
			<u></u>	

	<del></del>	0	1		•
,	100		2.37	484	
	kajar kara da kakenake representar		e water to the	near thomas is a desirable depolition	energi erakontanak kenink menina menuli saruh saruh uni dibektuan dibektuan belara di garu di garuh di gapti d
	101		2.11	485	
	102	CH <sub>3</sub>	2.05	473 475	
	103		2.07	460 462	parentee en establiske kontrek station station fra visk visk van de kontrek stock en dicht. Die kontrek dichte
	:				
	104	H <sub>2</sub> C CH <sub>3</sub>	2.07	478	·
	105		2.18	476 478	
	106	Сн,	2.13	466	
tiviteliheliseliset kiran olatiniseliset matakan kapa irak	North Control of the	EH, EH,	N. P. SPING N. MSP	inga misong i dipublikagar d	galent er den sammande en man gemen man um men seg samt sen i besen ses film film skall som se skall sig skall
	107	о Сн <sub>а</sub>	2.05	440	

108		2.20	450
antigen of the transfer transfer.	H <sub>3</sub> C	ili e senta ni maji i	egy money , geologists
109	CH3	2.31	464
ı	CH <sub>3</sub>		
110	CH,	2.31	464
	н,с сн,		
111	H.C. CH.	2.29	464
112		2.22	462
113	PN H,C CH,	2.07	436
114	CH <sub>2</sub>	2.07	436
A martin from the properties designed	CH,		
	110 111 112	110 CH <sub>3</sub> 1111  112  113	109  109  110  110  111  111  112  2.22  113  2.20

TO THE STATE OF TH

	115		2.12	476 478	
	116		2.13	448	inggaverne des continues par par participants per la continue de c
entermente de la contraction d	a Maria and a superior and a superio				
	117	P H <sub>2</sub> C T <sub>OH</sub> ,	2.26	480	
	118	CH <sub>5</sub> CH <sub>5</sub>	2.29	478	·
		H,C' CH,			
	119	gaga ay	2.15	485	такорино не изменения корология в подне доституть на против поднить доституть на при при поднить и и поднить п
	120	5	2.52	472	
in allandesia care a	المعادمة ال	Mc a L		es, come gradia	mengan semban mengan kanggan panggan at semban kanggan dan kanggan kanggan kanggan kanggan kanggan kanggan kan

r			
121		2.52	452
	<b>)</b>		
	H,C Y		
	о, сн,		
122		2.63	475
NGC 1000 PARKER PROPERTY.	the trade programme was confident flower, a constructive transaction and according to the confidence of the 190 miles.	e extra su no la	and there is determined.
	<b>~</b>		
	N H <sub>s</sub> C CH,		
123	, se	2.53	464
	94.°		
	M <sub>1</sub> C		
404	CH <sub>s</sub>		
124	$\triangleright$	2.53	480
	~~\\\		
	N <sub>0</sub>		
alitarian ing palabahan pelabahan	est that despite during the production of the control of the contr	wyman na na	A CONTRACTOR DESCRIPTION
125	H,C	2.60	464
	<i></i>		
			,
	M.C.		
126	°04, ¢^C4,	2.47	468
		£. <del>7</del> 1	<del>-</del> 00
	M.C.		
at for an instruction parties.	the control of the second second control of the con	erent ent	ngg stantes (gradikilige)

POSA ŠKORIJSKO, LIKOS IKORIJE SVIBNIKA ROJE IL

	127	H/E	2.59	464
uti ya Palingineti. 2004 ili silah dalah kenalah kapa da sa	and the second of the second o	н,с См.	. Service to organize	region to the control of the second of the control
	128	EH <sub>5</sub>	2.61	537
	129		2.37	475
		CH <sub>0</sub>		
CARROTTE CONTRACTOR STANDARDS	130	He Control of the Con	2.58	534
		Hc CH,		
	131	a c	2.66	518 520
STORY SECURE STATE OF THE SECURE SECU	an and a state of the state of	CH.	, akens hi este .	inga shakinya i Kabilikilda
	132	192000 NA	2.54	494
•		M,E A		

_			,			
	133	Q	2.76	504		
-			0.00	470		
and the second s	134	HC CONTROL OF THE CON	2.60	478	gaseen eerd konstigaal kan sagak gastiin diigi soon oo ka siissa siin dii kaan soo too oo ka siissa	n en se
		н,с ,				
	135	He H	2.60	517		
	136	CH,	2.65	588	ng parananan kananggahak kanangan memindi dengan andangga akan akan dan sebagai sa 1970 mengan sebagai sebagai	e
ent plante partition of a state of state of the state of	and the state of t	CH <sub>3</sub>				
	137	CH. His	2.83	579		
	138	H.C.	2.60	476		·· · · · · · · · · · · · · · · ·
THE PROPERTY OF STREET STREET, AND ASSESSED AS A STREET, ASSESSED AS A STREET, ASSESSED AS A STREET, AS A STR	g Kulturan in Sakakuran ngamban	CH <sub>2</sub>				

THE PROPERTY OF THE PROPERTY O

	139		2.63	536
	140	Br CH,	2.69	542 544
ाः च मार्थः मिनिकास्योवस्य अस्य र प्रयोगस्य स्थितस्य स्थापन् स्थापन् स्थ	ig englis est stableesteerbeginde	ganga naganggapanak ng Lakina dalahaka karan nasa, nasika iki kalaka mnasi semben sa ikin sa kini ikin ikin n	N. Compared to the	i neg menega semestagi
		H,C. N, CH,		
	141		2.62	528 530
		H <sub>2</sub> C	0.00	,
- Lo Para Taglingre (barel 1966 e printe di Statista (1968 e printe di Statista (1968 e printe di Statista (19	142	South that the provide the contract of the con	2.68	589
	,	No. of Market		
	143	H <sub>Q</sub> C H <sub>Q</sub> C H <sub>Q</sub> C	2.61	521
	144	CH, CH,	2.58	478
- Committee (Control of the Control	ang ang Silang ang Pangangan Sanggan S	HC	The second of	ne i neg manga gerbebig

ŗ				
	145		2.70	492
	ļ	ς»,		
	}			
	Į	n.c.		
	ļ			
	146	ėч,	2.81	506
	146	<b></b>	2.01	
		~ ·		
,		H <sub>s</sub> c.		
	antalis aret situatuarian benimber	kalla ette kertikan ja kalla ette kertikan mana ette saatel et siimen aan aan aan aan aan aan saat saat saat	, w perts north	. The Month of the State of the
}	147	- CH <sub>6</sub>	2.77	522
	177	, c <sub>H</sub> ,		
	ļ	<b>~</b> d		
	ł			
`{				1
		CON, O. CH		
	148	4,C	2.77	506
	,,,	, And		
				}
		CH. ON N		}
	!	M <sub>e</sub> c		] . ]
	140	H <sub>2</sub> C	2.59	464
	149	$\stackrel{\longleftarrow}{\sim}$	2.09	1404
in in the confidence of the co	and the transfer of the second	Company the provide some substitution of the source of	r v sams noms	e i niggi et entre el cres habitatas i
			1	
'		0~~	-	
	}	H,C CH,	1	
		CH,	<b></b>	
	150		2.57	464
		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
	}	. ~		}
	1	CH,°Z		}
	[	H,O CH,		
	L	<u></u>	٠	

ſ			т	<del></del>	 
	151		2.27	486	
		ا ا			
		HC F OH			
	152	N.C.	2.60	478	
Displace that work of the displacement as a reco	Court in a New York the Constitution of the Co		. we are	e green energy z	na kalender na kantana kana ang kalender kalender ang talang kanala sa kalender ang kalender ang kalender ang Kalender kanang kan
ļ				'	
	ı	Hotologia		1	
Ī	153	No.	2.63	494	
	1			'	
ļ	i			'	
į		l na d			
		Tat, Lat,	<del> </del>	<u> </u>	
Ì	154		2.36	466	
				1	
				'	
ETER BESTELDER LEISE GETTE SERVERERARIEN AUF AN A	Kill and Indichantal partitions	estadoris granta esta caracterista de la constitución de la constituci	Leavest School	neg erin re i den releve d	e grande de transport de la companya
		H.C.	<u> </u>	<u> </u>	
	155		2.36	466	
	1			!	
				,	
	1				
		40-0		1	
	156	CH <sub>3</sub>	2.65	478	-
	150	\ \_\\	2.00	410	
1	1			1	
!	1				
nutur Betretarturren atur etatarrakiari eta erre	the transfer of the second consideration of	HC HC	January 15, 116	ngs transcer significance d	an neurona mentre de la companya de
!					
1		СН,	1		J

	157	H <sub>C</sub>	2.54	464
i di kalanda k	158 .	CH <sub>3</sub> CH	2.40	450
	159	H,C N	2.42	493
	160	H <sub>s</sub> C CH <sub>s</sub> O CH <sub>s</sub>	2.42	561
Outer of the Angeles and Control of the Angeles and An	161	H <sub>c</sub> C N	2.51	500 502

	162	🖒	2.66	492	
२२२ मध्य १२८ विद्यास्य १८४८ । स्वयं र १४८८ विद्यासम्बद्धाः स्वयं स	gangati and industrial parties by the control	MA COMPANY OF THE COM	oli, wi godina i No. me	The state of the s	province province extra ex
1					
		<u>-</u>			
	163	, on	2.60	528	
		0		530	·
		r+2.			
	164	~ ~~~	2.54	522	
			a, was was a me	ng makaya garagalisa	Baselining Berganas kan ay mamenara mga sa sala an shikar sa masa sa sa sa sa sa
चेत्राच्याच्यात्रस्य स्थापन्ते । स्थापन्ते स्थापन्ते । स्थापन्ते स्थापन्ते । स्थापन्ते स्थापन्ते स्थापन्ते स्थ स्थापन्ते स्थापन्ते	AND OUT OF SOMETHINGS	para out raggeria ser uson entresemblen eine eine eine einem entre einem einem einem einem einem einem einem e Einem einem ein			,
	165	T	2.51	462	
ļ		0,000			
		H.,			
ļ	166		2.76	565	,
OPERATOR STANDARD ST	alle and the state of the state	namanua saassama waxaa asaa saasaa wana way ifa affa waxaa maa saasa xaasa xaasa waxaa waxaa waxaa waxaa waxaa	tally or search to the con-	a comparation is contracted	appunkki kinder kanada kinder kinder kanada kinder kinder kinder kinder kinder kinder kinder kinder kinder kin
	167		2.55	504	
		0-1-0-0-6			·
	1	, <del>                                    </del>			

Γ	168	м <sub>ю</sub> —сы <sub>з</sub>	2.51	464	
			1		
o monocologico por la cologica de la	and our resources	kana kana kana kana kana bana dan kana kana kana kana kana da kana kan	Law perfects in the	, the state of the state of	personal series in the series of the series
			<u></u>		
	169	0-000	2.67	490	
		5.0			
}		/ <del>-</del> /	0.45	480	
	170	0,-0,-0,-0,-	2.45	480	
		+4.			
	171		2.57	504	angeneri en mentember anne parte dage ett pleas villaten et bleve en beste en stelle en et bleve et be
, por en en el entre de la companya	antati are in the secretaring where		and the first	506	Reput to the testing of the period server of the server of
	172	j. bu	2.63	478	
		H <sub>2</sub> C + CH <sub>2</sub> C + CH <sub>3</sub> C			
	173	CIL	2.65	494	
. Ser ment planter productives, a consequence of productive productives and service and	angle and the sound and the sound	mengananggan kepadahan dia salah salah dia kepadah dia salah dia kepadah dia salah salah dia salah dia salah d Salah salah sa	10 . W 2 675.1 Fz. 47.1	to . The months of performance	e gagasini nesika negagasi suodasi paginti agasii troprosis olastian. Sidatu in 1000 km, 1000 km, 1000 km, 1000
		Mac Cold Cold		,	

WO 2004/035556 PCT/EP2003/011423

	174	N CH4,	2.69	478	
alle for the second of the second	Book and the book of the beginners as	H <sub>C</sub> L <sub>A</sub>	and particles one	Towns towns	gavernerønneggavenskessav sagne agenetast og itt var finan og till en elle i kalle
And the Table States and the American States and the States and th	175	S CH,	2.56	482	
	176	O, CH,	2.49	502	
ବର ଓ ମିଧି ବିଧାର ଓ ଅଧିକର୍ଷ ଓ ପର ବିଧାରଣ ବିଧାରଣ ବିଧାରଣ କଥିଲି ।		N <sub>C</sub> CH <sub>s</sub>			a promotive de comencia e promotive de promotive de la comencia de la comencia de la comencia de la comencia d
	177	H <sub>C</sub> C CH <sub>1</sub>	2.66	478	

1		T UC - 0:		т	~
	178	o de la companya de l	2.55	514 516	
erinningsbyreine var erinne blike blike blike blike blike blike	and the design of the second	SANGE MAN DE LA CAMBRICA CAMBRICA CAMBRICAN COMPANION CONTRACTOR C	garante del major y	ings stooty of programs B	againe en ne sanagain na na seann na gailtean an chuir an chuir ann an t-airean an 1808 an 1808 an 1808 an 180
TOTAL STOREST CONTRACTOR CONTRACT	N. D. C. William Brown	Ст <sup>№</sup> сн <sub>ь</sub>			
	179		2.47	448	
	180	CH <sub>1</sub>	2.72	551	
o en en el los entres de estado en estado en el contrato en en el entres de entres en el entres en el entres e	gill von Entwerpteroppertreet	and the second s	er generality to a more of	, which is a second of the sec	водинення на продрами до до проделя дости под
	181		2.52	560	
			;		
	182	°, ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	2.47	489	
io dan da propositiva de la companie	ACC TO DEPOSIT AND	CH <sub>3</sub> CH <sub>4</sub> CH <sub>5</sub>	e parts to rese	englise market in distribute state of the	a popular employational extrapor properti tango trapit via station in terminos (1 o 1 order statinos o 1 o 1
•					•

	183	F—F	2.54	490		
					· 	
		$\checkmark$				
		<b>М</b> Сн,				
es consequinament est a consequencia de la consequencia de la consequencia de la consequencia de la consequenc	and the second s	H <sub>C</sub> C	2.47	450	and the second section of the second section section section sections are second section sections.	the translations as
	184	O CH <sub>3</sub>	2.41	450		
		<u>(</u> ^)				
				ļ		
	i					
		م	ŀ			
					·	
		CH <sub>3</sub>				
	185	ÇH <sub>5</sub>	2.60	476		
	186	$\bigcirc$	2.39	466		
		, Andrews				
is de la composition	and the second second	man kang manggaran kang alaman sensi kang alaman kang bankan di dipanangan berman kang bankan dari berman berm	tons, as payents to, and	e yes areasery is appropriately	et i gestaande de statier van de kommende de statien de statien de statien de statien de statien de statien de De statien de statien d	e tur ti erri etali ea cila
		· · · · · ·				
		H,C-0				
·	407	ÇI	2.53	491	_	
	187	CI	2.50	130		
			l			
		\ \rightarrow \cdot				
SOUTH AND CONTRACTOR OF THE STATE OF THE STA	and the second of the second o	CH C	many partition	to a sign or solve a discovery	eur passan er en met ræmagt men staget spæmtet dær in 1941 og 1941, blet i Stefans	a per serenta. C
			_			

	188		2.63	478		
		N.C. CH.				
	189		2.64	494		
	l					
es es secretar de reportación de la companya de la	ang		عارفة إنفاريو فالمعارو	a	nin stapparti er de endistablik kombe stattet dit "e 1755 i 1811.	signati (kensiya tin toki igid keylan i
		NG CHY CHY				
	190	OH,	2.68	478		
		MC C				,
		OH,				
	191	сн,	2.58	482		
					en seguero e e encompaño e en un partir mejo 17 po che	Street substitute of the substitute of
nder der State State der Geber der der State der State S	araja shiilii aran iin birka sinaariisaa iyaariin	regenta esta teatra per casa esta casa esta casa esta esta esta en esta entre entre entre en esta esta esta esta en esta en esta en esta entre				
		H <sub>2</sub> C				
	192	ÇH,	2.55	464		
	ļ					
		A STATE OF THE STA				
		l na l				
	L	] ск,	L			

_				
	193	H, C	2.44	450
Significant for the state of th	194	H <sub>3</sub> C	2.47	500 502
		H,C		
all defining the control of the cont	195	Ha Land	2.66	478
	196	by the contract of the contrac	2.44	508
	197	H <sub>C</sub> C <sup>CH</sup> ,	2.44	448

n de la company de la comp	198	tanag nagawata sa laga taasaa asaa asaa ay yoo i ilaasana saasa saasa saasa saasa sa saasa sa sa	.2.71.	-554	epikan eki den sembada kika bilah pembadagan bilah sebuah dalam 1992 yang bilah bilan dalah sang bilan sang bilan sa
		**O-O-			
	199	5 <sup>4</sup>	2.52	560	
	100				
		<b>Y</b>			
		ÇH <sub>3</sub>			
	200		2.46	489	
TO A STATE OF THE	and the second second	the rest that the rest was producted from the rest of	west to make	en et eers oorgenigelijkel is	esiden del destala del se se sus propositiones en la colonida del 1990 en 1990 en 1990, del 1990 en 1990 en 19
		CH <sub>a</sub>			
	201	ьц гг	2.50	490	,
					, i
			:		
		H,C	i		
	202	н,с	2.46	450	
		о сн,			
LO COMETA, PROPERTO DE LA PARTE PROPERTO MARIA A PARTE.	and the control of the state of	N Control of the Control of Contr	A APPENDING TO	, They are notice to describe property of	a para ne managana kabana na para na mana na pangana na pangana na pangana na pangana na pangana na pangana na
					·
		H <sub>s</sub> c —		1_	

203 2.62 476	
H <sub>2</sub> C~~~~~	
STORE THE PROPERTY OF THE PROP	tropical capital and tradecimal business and capital in
204	
Сн,	
205	
The state of the s	a traje dia diala dan Malandia Kondonin Kadil kadilah di
H <sub>C</sub> C	
206 2.40 508	
207 M <sub>O</sub> 2.37 496	
CONTRACTOR AND	um i gran em em mez ment i committe de distribución de designativos de la filia.
CH <sub>2</sub>	

	208	CH, OH,	2.35	478	
		H <sub>3</sub> C OH			
TO STORE THE PROPERTY OF THE STATE OF THE PARTY OF THE PARTY.	an ar inspectation	in the the production of the section	e skens no est .	ng manya georgeans	epiero residenti ambani kanta kantara pembara depus trapo nekonda kero. Sekaran kentara banda kantara kentara Sekaran kentaran kentara kentara kentaran depus trapo nekonda kentaran kentaran kentaran banda kentaran kentar
	209	H,c CH, C	2.27	464	
	210	O CH,	2.37	504	
The process of the financial conduction of the process of the conduction of the cond		CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> CH <sub>4</sub>		506	anders et dies stateman de state de stateman digen uit van de stateman in de stateman die 1 de seu en 1800 fac
	211	Э	2.26	514 516	·
	212	BI CHA	2.34	528 530	
. Secretaria de la compositorio de	S (2014) Control of the Control of t	The state the state of the stat	skritt in med	. And the service of the service of	a participa de la companya de participa de participa de la companya de la companya de la companya de la company

	213	No. I on	2.00	514
:		NC COL		
- Production (Productive Land Confidence) (Production Associated Association Confidence)	214	F	2.28	522
er et en		H <sub>2</sub> C CH <sub>3</sub>		
	215	M.C.  Cont.  Cont.  Cont.	2.26	462
ত । বাধান্ত নিজন ক্ষেত্ৰ	216		2.57	574
·		Mc CM		
	217	F CH <sub>s</sub>	2.30	503
LD 1707 SATER (PROSE) (1995), LOS AN ANTON 1985 (PARTIES AND	218		2.30	504
		no S		

 $p_{\rm physics}(a,a,b,c) = p_{\rm physics}(a,b,c) + p_{\rm physics}(a,b,$ 

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

8
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

### IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.